-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the deepening of global aging, increasing work intensity, and changing life>
.
It is worth mentioning that while the current ophthalmology market is showing rapid growth, a large number of companies are also accelerating their entry into this market
.
Recently, many pharmaceutical companies have announced that they will increase their layout in this field
.
For example, recently, Cloudbreak Pharma, Inc.
(hereinafter referred to as Baiyun Pharmaceutical), an innovative ophthalmic drug developer, announced the completion of US$130 million in Series C financing
.
According to the data, Boyun Pharmaceutical is a very representative and outstanding enterprise in the field of innovative ophthalmic drugs.
It has been committed to improving the success rate of product research and development and the market through the product development model and differentiated positioning of 505b(2) on the basis of insisting on innovation.
Prospects
.
It is understood that this round of financing will be used for the company's multiple product pipeline clinical trials, registration and commercialization preparations, GMP pilot plant construction, improvement of the company's production capacity to international standards, and team expansion
.
In addition, recently Lineage Cell Therapeutics also announced that Lineage and its subsidiary Cell Cure Neurosciences have reached an exclusive global cooperation and licensing agreement with Roche's Genentech for the development and commercialization of a OpRegen, a cell replacement therapy based on retinal pigment epithelial cells (RPE), is used to treat eye diseases, including advanced dry age-related macular degeneration (AMD) with geographic atrophy (GA)
.
According to the cooperation agreement, Lineage will complete the activities related to the ongoing clinical trials (the trials have been enrolled) and will be responsible for certain production activities
.
Genentech will pay Lineage an upfront payment of US$50 million, as well as additional development, approval and sales milestone payments of up to US$620 million, as well as tiered royalties for future product net sales.
.
It is worth noting that, in the face of the huge market scale of ophthalmic drugs, in addition to the continuous acceleration of foreign pharmaceutical companies' deployment of ophthalmic innovative drugs; Chinese pharmaceutical companies are also constantly pouring into the ophthalmic innovative drug track
.
For example, in June 2021, Ruiming New Medicine announced the completion of nearly 100 million yuan in A+ round of financing, led by Huimei Capital, and the old shareholders Taiyu Investment and Shengding Pharmaceutical Investment continued to make additional investments
.
This round of financing will be mainly used for the IND application and clinical exploration of the company's various products and the introduction of new projects
.
In April 2021, Vision Bio, which focuses on the development of innovative drugs for the treatment of ophthalmic diseases such as dry eye and glaucoma, also announced the completion of 300 million yuan in round D financing
.
It is reported that this round of financing will be used to support the clinical development of a number of innovative ophthalmic drug products, including the ongoing dry eye project VVN001 US clinical phase II study
.
On the whole, in recent years, with capital intervention and talents returning to China to start businesses, domestic new ophthalmic drug companies have sprung up like bamboo shoots after a rain
.
At present, there are Ruiming New Drugs and Weibo Biology on the small molecule circuit, and Cinda, Kanghong Pharmaceutical and other companies are also on the macromolecule circuit
.
In this context, the industry believes that with the continued support of policies and capital in the future, many pharmaceutical companies will continue to pour into this track, and more innovative ophthalmic therapies will continue to emerge
.
.
It is worth mentioning that while the current ophthalmology market is showing rapid growth, a large number of companies are also accelerating their entry into this market
.
Recently, many pharmaceutical companies have announced that they will increase their layout in this field
.
For example, recently, Cloudbreak Pharma, Inc.
(hereinafter referred to as Baiyun Pharmaceutical), an innovative ophthalmic drug developer, announced the completion of US$130 million in Series C financing
.
According to the data, Boyun Pharmaceutical is a very representative and outstanding enterprise in the field of innovative ophthalmic drugs.
It has been committed to improving the success rate of product research and development and the market through the product development model and differentiated positioning of 505b(2) on the basis of insisting on innovation.
Prospects
.
It is understood that this round of financing will be used for the company's multiple product pipeline clinical trials, registration and commercialization preparations, GMP pilot plant construction, improvement of the company's production capacity to international standards, and team expansion
.
In addition, recently Lineage Cell Therapeutics also announced that Lineage and its subsidiary Cell Cure Neurosciences have reached an exclusive global cooperation and licensing agreement with Roche's Genentech for the development and commercialization of a OpRegen, a cell replacement therapy based on retinal pigment epithelial cells (RPE), is used to treat eye diseases, including advanced dry age-related macular degeneration (AMD) with geographic atrophy (GA)
.
According to the cooperation agreement, Lineage will complete the activities related to the ongoing clinical trials (the trials have been enrolled) and will be responsible for certain production activities
.
Genentech will pay Lineage an upfront payment of US$50 million, as well as additional development, approval and sales milestone payments of up to US$620 million, as well as tiered royalties for future product net sales.
.
It is worth noting that, in the face of the huge market scale of ophthalmic drugs, in addition to the continuous acceleration of foreign pharmaceutical companies' deployment of ophthalmic innovative drugs; Chinese pharmaceutical companies are also constantly pouring into the ophthalmic innovative drug track
.
For example, in June 2021, Ruiming New Medicine announced the completion of nearly 100 million yuan in A+ round of financing, led by Huimei Capital, and the old shareholders Taiyu Investment and Shengding Pharmaceutical Investment continued to make additional investments
.
This round of financing will be mainly used for the IND application and clinical exploration of the company's various products and the introduction of new projects
.
In April 2021, Vision Bio, which focuses on the development of innovative drugs for the treatment of ophthalmic diseases such as dry eye and glaucoma, also announced the completion of 300 million yuan in round D financing
.
It is reported that this round of financing will be used to support the clinical development of a number of innovative ophthalmic drug products, including the ongoing dry eye project VVN001 US clinical phase II study
.
On the whole, in recent years, with capital intervention and talents returning to China to start businesses, domestic new ophthalmic drug companies have sprung up like bamboo shoots after a rain
.
At present, there are Ruiming New Drugs and Weibo Biology on the small molecule circuit, and Cinda, Kanghong Pharmaceutical and other companies are also on the macromolecule circuit
.
In this context, the industry believes that with the continued support of policies and capital in the future, many pharmaceutical companies will continue to pour into this track, and more innovative ophthalmic therapies will continue to emerge
.
